GlaxoSmithKline plc (GSK) and Innoviva, Inc. announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an ...

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Nov 18, 2013) - GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced today that the European Commission has ...

GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved RELVAR™ ELLIPTA™ for the treatment ...

The European Commission approves new labeling for GlaxoSmithKline's (NYSE:GSK) Relvar Ellipta (fluticasone furoate/vilanterol) to include patients adequately controlled on both an inhaled ...

LONDON & BRISBANE, Calif.--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the start of a phase III study investigating the effects of once-daily ...

Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ®. In addition, Innoviva retains a 15 percent economic ...

Theravance Inc. will pay GlaxoSmithKline $15 million for winning European approval of the lung disease treatment Relvar Ellipta and will pay out another $15 million when GSK launches the drug ...

The FINANCIAL — GlaxoSmithKline and Theravance, Inc. on September 24 announced the intention to file a supplemental Japanese New Drug Application (sJNDA) for Relvar Ellipta (fluticasone furoate ...

GlaxoSmithKline plc GSK and partner Innoviva, Inc. INVA announced that the FDA has granted approval to its medicine Trelegy Ellipta for a new asthma indication. The FDA has approved the triple ...

(RTTNews) - Innoviva, Inc. (INVA) and GlaxoSmithKline plc (GSK, GSK.L) announced Thursday that the European Commission has approved a label update to Relvar Ellipta in patients with asthma. The label ...